MARCUS: A proposal to put young people to work
The Rockefeller Foundation has called for ideas that address the nation’s youth unemployment situation. Here are mine:
The Rockefeller Foundation has called for ideas that address the nation’s youth unemployment situation. Here are mine:
Unlike similar lists for the live arts, movie top 10 lists tend to generate more push-back. That’s because audiences have greater opportunity to see the work for themselves and formulate their own opinions.
As major arts institutions in central Indiana search for administrative leadership and financial stability, a logical question might be, what should be the role of the board for a not-for-profit organization?
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
My job takes me out of my office into the community on a regular basis. As I’m out talking with folks in the business community, a common theme surfaces almost without fail on a weekly basis.
This is the last column before Christmas, and in keeping with long tradition, I’m writing a year-end column about screw-ups and techno-pratfalls that should make you glad you’re not in the hottest of hot seats.
From the mid 1980s through perhaps 2008, automotive investment in the Great Lakes region was driven by General Motors, Ford and Chrysler losing market share to competitors from Japan, Korea and Europe.
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
Indiana seems to be experiencing a fresh outbreak of reefer madness.
Battle lines for the next General Assembly are evident already.
Mitch Daniels will leave the governor’s mansion to a chorus of hurrahs from budget-balancers, conservative pundits and the Republican Party, which wishes—now even more than before—that he had run for president. But what can other Midwestern states learn from the Daniels era?
The founder of a cheerleading-supply company will become the next CEO of Indianapolis-based Herff Jones Inc., one of the city's largest private companies.
Muhammad Yasin began heading up social media marketing at Indianapolis-based HCC Medical Insurance Services LLC in early 2011. The company, which sells travel insurance and short-term medical insurance online, credits his work with tripling overall revenue in 2011 to more than $60 million and growing even more this year. Yasin, along with a steady stream of interns, manages nearly 50 social media accounts on Facebook, Twitter, Pinterest and YouTube, and has about 400,000 total followers. Collectively, HCC’s social media team produces 2,000 pieces of “content” every month—even though it operates in a highly regulated industry.
The RND Group Inc., which makes software for medical-device and diagnostic firms, will expand its operations in Indianapolis, adding as many as 25 jobs by 2016. The company employs 27 full-time people along with the equivalent of 14 full-time contractors. The Indiana Economic Development Corp. agreed to give RND Group $700,000 in tax credits if it fulfills its job-creation commitment. The city of Indianapolis is considering additional tax incentives.
Indianapolis-based Nico Corp. has raised another $6.5 million in venture capital from its existing shareholders and board members. Nico’s Myriad line of products allow minimally invasive removal of brain tumors and tissue in adults and children. Now, Nico wants to use the new round of capital to develop technology to address diseases that were often considered inoperable, such as metastatic brain cancer, intracerebral hemorrhages and glioblastoma multiforme. Since 2008, Nico has raised $20 million, with half of that coming in 2009. Investors participating in its latest fundraising round included Rose-Hulman Institute of Technology, River Cities Capital Fund, CHV Capital, Cornelius Private Investments and Twilight Venture Partners. Nico was founded in 2007 by many of the executives and investors that created Suros Surgical Systems Inc., which was sold in 2006 to Massachusetts-based Hologic Inc. for $248 million.
West Lafayette-based Perfinity Biosciences Inc. has partnered with Japan-based Shimadzu Corp. to market and distribute its technology, which automates the preparation and analysis of protein samples in research and diagnostic labs. The Perfinity Integrated Digestion Platform cuts down sample preparation time from 18 hours to 30 minutes or less. The companies worked together to launch Perfinity’s technology in the United States earlier this year. Financial details about the agreement were not disclosed.
Micro Machine Co. LLC, an orthopedic medical-device manufacturer, will build out a new manufacturing plant in Warsaw, creating as many as 60 jobs by 2015. The company, based in Kalamazoo, Mich., will invest $2.8 million in its expansion to produce parts for Warsaw-based Zimmer Holdings Inc. and Warsaw-based DePuy Orthopaedics Inc., and perhaps other companies. Micro Machine already employs eight in Warsaw in addition to 72 in Kalamazoo. The Indiana Economic Development Corp. offered Micro Machine up to $585,000 in tax incentives and training grants if it fulfills its job-creation plans. Kosciusko County approved additional property tax abatement for Micro Machine.
While Eli Lilly and Co.’s stock price is up 16 percent in the past four months, a new analyst covering the company thinks it has more room to grow. And that’s even without launching a new Alzheimer’s drug anytime soon.
The Indiana Historical Society has raised $19.5 million to support the Indiana Experience, its series of interactive history lessons intended to draw more visitors to the local not-for-profit’s downtown facility.
Catamaran Corp. will add 50 jobs in Indianapolis over the next year to help it provide pharmacy-benefit-management services to the Indiana Medicaid program. The Illinois-based company will open an office downtown Tuesday to kick off its six-year, $60 million contract with the state. The contract, which officially begins April 1, pledges Catamaran to help Indiana Medicaid control the $800 million it spends every year to provide prescription drugs to Medicaid recipients. Catamaran will process Indiana Medicaid’s 12.5 million annual pharmacy claims, run clinical and technical call centers, handle electronic prescriptions and manage specialty medications. The Indianapolis office, located at 150 W. Market St., will house pharmacists, technicians and support staff.
Two investors in Indianapolis are trying to raise money to fill the gap in early-stage funding for life sciences companies in the Midwest. San Francisco-based CMEA Capital is trying to raise $100 million for early-stage life sciences investments, according to multiple people briefed by CMEA’s Midwest partner in the fund, Kent Hawryluk. Hawryluk, a co-founder of Carmel-based drug development firm Marcadia Biotech, will oversee Midwest investments of the fund from Indianapolis, with a focus on biotech and pharmaceutical companies, according to people familiar with his plans. In addition, Oscar Moralez, managing director of the StepStone Angels network, plans to start pitching a new fund to investors early next year. His plans are to raise $10 million to $20 million to invest in technology companies, including life sciences firms, in Indiana and surrounding states. “We feel the timing is right,” said Moralez. He described the fund he wants to raise as, in part, a "sidecar" to help the seven companies now supported by StepStone Angels—six of which are life sciences companies—to continue to get the cash they need to grow.
Due to the closing of Franciscan St. Francis Health’s Beech Grove hospital, Select Specialty Hospital-Beech Grove relocated from Beech Grove to a new freestanding location at 8060 Knue Road in the Castleton neighborhood. In its new location, Select Specialty Hospital has 45 beds, on-site CT machines, lab services, a rehabilitation area and a cafeteria. The hospital will now be called Select Specialty Hospital – Indianapolis.
A North Carolina-based maker of cancer-fighting ultrasound machines plans to create 27 jobs at its Indianapolis facility over the next three years. US HIFU LLC will add positions paying an average of $36 an hour at its offices at 4000 Pendleton Way, on the northeast side of the city along Interstate 465 near Pendleton Pike. The company already employs 15 people at that location. The new jobs are for engineers, researchers and support personnel to help US HIFU make its Sonablate 500 system, which uses "high-intensity and focused ultrasound" to treat cancer with fewer side effects. US HIFU, founded in 2004, has yet to receive regulatory approval for its technology, but the company is studying it in a U.S. clinical trial for treating prostate cancer and around the world as a potential treatment for other cancers. The new jobs were announced Monday morning by the Indiana Economic Development Corp., which promised the company up to $350,000 in conditional tax credits and up to $50,000 in training grants. Also, the company has applied to Marion County for property tax abatement.
Novia CareClinics LLC opened the first multi-employer clinic for downtown employers Monday at its headquarters at 429 N. Pennsylvania St. Novia, which operates 50 clinics statewide, made its latest clinic open to other employers. Harrison College, the law firm Plews Shadley Racher & Braun LLP and McFarling Foods Inc. have joined so far. The 1,200-square-foot health and wellness center, first made public in July, will be staffed with a physician and nurses, offering primary care services 40 hours per week. The four companies using it have more than 500 employees combined at locations in or near downtown. Novia has said it needs to sign up 1,000 employees to make the cost per employee reasonable. If employer demand proves high, Novia could expand its downtown clinic to as large as 2,000 square feet, add a second physician or nurse practitioner, and serve as many as 2,000 employees.
European Union regulators have agreed to review the drug vintafolide, discovered by West Lafayette-based Endocyte Inc., bringing it one step closer to reaching the market. Endocyte and its development partner, New Jersey-based Merck & Co. Inc., said the European Medicines Agency will review vintafolide, formerly known as EC145, as a treatment for ovarian cancer that is resistant to platinum-based chemotherapy. The agency also will review their application for an imaging agent that can help identify patients most likely to benefit from the drug. According to the Associated Press, vintafolide and the diagnostic agent both have orphan drug status, which means competing products will be barred from the market for up to 10 years if they are approved. Merck will pay Endocyte $5 million because the application was accepted.
The government dropped its antitrust concerns about health insurer WellPoint Inc.'s proposed acquisition of Amerigroup Corp. last week, clearing WellPoint to proceed with the $4.9 billion deal. According to the Associated Press, U.S. Department of Justice officials had objected to the proposed merger because WellPoint and Amerigroup are the only providers of Medicaid managed care plans in northern Virginia. To address that concern, Amerigroup agreed to sell its Virginia business, Amerigroup Virginia Inc., to Inova Health System Foundation. It did not disclose financial terms of that deal, which was announced in September and is conditioned on the closing of the WellPoint-Amerigroup merger. The sale to Inova ensures that Medicaid users will have at least two options for managed care, the Justice Department said.
Automakers and suppliers are pumping more money into research and development at a time many of their sales departments struggle with a slowing global economy.
At some point over the past generation, people around the world entered what you might call the age of possibility. They became intolerant of any arrangement that might close off their personal options.
China takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.